利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1486 条记录 (耗时 0.02 秒)

    DEVELOPMENT OF NOVEL PDL1 SINGLE-DOMAIN ANTIBODY
    2.
    发明公开
    DEVELOPMENT OF NOVEL PDL1 SINGLE-DOMAIN ANTIBODY 审中-公开

    公开(公告)号：EP4458855A1

    公开(公告)日：2024-11-06

    申请号：EP22915220.2

    申请日：2022-12-30

    申请人： Persongen Biotherapeutics (Suzhou) Co., Ltd.

    发明人： YANG, Lin ,  YOU, Fengtao

    IPC分类号： C07K16/28 ,  C12N15/13 ,  C12N15/85 ,  A61K39/395 ,  A61K51/10 ,  A61K35/00

    摘要： Disclosed are a nanobody for PDL1 and a use thereof. Provided are a nanobody for PDL1 and a sequence thereof. Also provided are a polynucleotide encoding the nanobody, a corresponding expression vector, a host cell capable of expressing the nanobody, and a method of producing the nanobody. The nanobody can specifically bind to human PDL1 and has a high affinity as well as an excellent PD-1/PDL1 blocking activity. The nanobody can block only PD-1 and PDL1 pathways without affecting PD-1 and PD-L2 pathways, thereby avoiding side effects such as interstitial pneumonia as well as increasing safety. The nanobody can also more comprehensively activate the immune system to kill tumors, and the curative effect can be achieved for patients for whom PD-1 is ineffective or who are resistant to PD-1. The PDL1 nanobody can not only inhibit the PD-1-PDL1 pathway but also inhibit the co-inhibition function of B7.1 and PDL1, so that the T cell function and cell factor generation can be comprehensively activated, thereby achieving an improved immune effect.